Inhibition of fatty acid amidohydrolase (FAAH), the enzyme responsible for the selective in vivo degradation of the endocannabinoid anandamide, elicits CB1 receptor-mediated anxiolytic, analgesic and cardiovascular depressor effects, without inducing behavioral effects that would indicate addictive potential. In an earlier collaborative study with Dr. Andrew Holmes'group, we used the novel FAAH inhibitor AM3506 to test its therapeutic potential in PTSD, using a mouse model of fear extinction. We found that AM3506 elevated anandamide levels in the amygdala, facilitated fear extinction and this effect was reversed by CB1 antagonist treatment, raising the possible therapeutic use of AM3506 in PTSD. These findings were published in 2012 in Molecular Psychiatry with Dr. Holmes as corresponding author. While doing this study, we found that a single dose of AM3506 caused complete inhibition of FAAH that lasted more than 48 hours, due to the irreversible (covalent) mechanism of blocking FAAH activity. However, the corresponding rise in brain anandamide levels was transient and lasted <2 hours. This suggested that in the absence of FAAH activity, anandamide can be metabolized by other enzymes, such as COX-2, as suggested by a recent study (Nat Neurosci 16:1291, 2013). We therefore extending this project, in continued collaboration with Dr. Holmes'group, to test whether a) combined treatment of mice with AM3506 and a novel, substrate-selective COX-2 inhibitor prolongs the elevation of tissue anandamide levels, and b) in that case whether it also potentiates extinction in a fear paradigm.

Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2013
Total Cost
$433,090
Indirect Cost
Name
National Institute on Alcohol Abuse and Alcoholism
Department
Type
DUNS #
City
State
Country
Zip Code
Gunduz-Cinar, Ozge; Flynn, Shaun; Brockway, Emma et al. (2016) Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids. Neuropsychopharmacology 41:1598-609
Gaskari, Seyed Ali; Liu, Hongqun; D'Mello, Charlotte et al. (2015) Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids. J Hepatol 62:1272-7
Kunos, George; Volkow, Nora D (2013) Preface to the special issue of psychopharmacology: 10ýýyears of the Jacob P. Waletzky Award. Psychopharmacology (Berl) 229:383-4
Gunduz-Cinar, O; MacPherson, K P; Cinar, R et al. (2013) Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 18:813-23
Depoy, Lauren; Daut, Rachel; Brigman, Jonathan L et al. (2013) Chronic alcohol produces neuroadaptations to prime dorsal striatal learning. Proc Natl Acad Sci U S A 110:14783-8
Bashashati, M; Storr, M A; Nikas, S P et al. (2012) Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br J Pharmacol 165:1556-71
Engeli, Stefan; Bluher, Matthias; Jumpertz, Reiner et al. (2012) Circulating anandamide and blood pressure in patients with obstructive sleep apnea. J Hypertens 30:2345-51
Heilig, Markus; Warren, Kenneth R; Kunos, George et al. (2011) Addiction research centres and the nurturing of creativity: the National Institute on Alcohol Abuse and Alcoholism. Addiction 106:1052-60
Seif, T; Makriyannis, A; Kunos, G et al. (2011) The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing. Neuroscience 193:21-33
Zhang, X; Maor, Y; Wang, J F et al. (2010) Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol 160:1583-94

Showing the most recent 10 out of 16 publications